| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2018-04-25 | AVXS-101 (adeno-associated virus serotype 9 expressing the human Survival Motor Neuron gene) | spinal muscular atrophy (SMA) Type 1, 2, 3 | 3 | Avexis (USA - IL) | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2018-04-24 | AVXS-101 | spinal muscular atrophy (SMA) Type 1 | 1 | Avexis (USA - TX) | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2018-04-24 | AVXS-101 (adeno-associated virus serotype 9 expressing the human Survival Motor Neuron gene) | spinal muscular atrophy (SMA) Type 1 | 3 | Avexis (USA - IL) | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2018-04-23 | Vabomere™ (formerly known as Carbavance) meropenem-vaborbactam | complicated urinary tract infections (cUTI) | 3 | Melinta Therapeutics (USA - CT) | Infectious diseases |
| 2018-04-23 | RX-P2382 | preclinical | Melinta Therapeutics (USA - CT) | Infectious diseases | |
| 2018-04-23 | omadacycline | community-acquired bacterial pneumonia (CABP) | 3 | Paratek Pharmaceuticals (USA - MA) | Infectious diseases |
| 2018-04-17 | ATOR-1015 | preclinical | Alligator Bioscience (Sweden) | Cancer - Oncology | |
| 2018-04-17 | Aimovig™ - AMG 334 (erenumab) | migraine | 3b | Amgen (USA - CA) Novartis (Switzerland) | CNS diseases |
| 2018-04-17 | monalizumab (IPH2201) and cetuximab | squamous cell carcinoma of the head and neck | preclinical | Innate Pharma (France) | Cancer - Oncology |
| 2018-04-17 | monalizumab and durvalumab | solid tumors | preclinical | Innate Pharma (France) | Cancer - Oncology |
| 2018-04-17 | antibody against Siglec-9 | preclinical | Innate Pharma (France) | Cancer - Oncology | |
| 2018-04-17 | IPH52 and IPH53 | preclinical | Innate Pharma (France) | Cancer - Oncology | |
| 2018-04-17 | monalizumab (IPH2201) and cetuximab | relapsed or metastatic squamous cell cancer of the head and neck (SCCHN) | 1b-2 | AstraZeneca (UK) Innate Pharma (France) | Cancer - Oncology |
| 2018-04-16 | tislelizumab (BGB-A317) | relapsed or refractory mature T- and natural killer (NK)-cell lymphomas | 2 | BeiGene (China) | Cancer - Oncology |
| 2018-04-16 | pamiparib (BGB-290) | locally advanced or metastatic high-grade non-mucinous ovarian cancer (HGOC), including fallopian cancer, or triple-negative breast cancer (TNBC), who had disease progression following at least one line of chemotherapy | 1 | BeiGene (China) | Cancer - Oncology |
| 2018-04-13 | MIV-818 | hepatocellular carcinoma and other liver cancers | preclinical | Medivir (Sweden) | Cancer - Oncology |
| 2018-04-12 | PF-06939926 (mini-dystrophin) Recombinant adeno-associated virus serotype 9 vector expressing codon-optimized miniaturized version of DMD gene | Duchenne muscular dystrophy (DMD) | 1b | Pfizer (USA - NY) | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2018-04-12 | AB-506, AB-452 in combination with ARB-1467 and approved HBV therapies | hepatitis B | preclinical | Arbutus Biopharma (Canada) | Infectious diseases |
| 2018-04-10 | tislelizumab (BGB-A317) | previously treated advanced hepatocellular carcinoma | 2 | BeiGene (China) | Cancer - Oncology |
| 2018-04-09 | tazemetostat - EPZ-6438 (E7438) | advanced solid tumors and B-cell non-Hodgkin lymphoma (NHL) | 1 | Epizyme (USA - MA) | Cancer - Oncology |
